Royce Micro-Cap Trust

RMT

Market cap $757M

Royce Micro-Cap Trust is rated a Buy, driven by strong YTD performance, a widening -12% discount, and a 6% yield likely to rise. RMT's managed distribution policy targets 7% of rolling NAV, with distributions growing alongside NAV and robust capital gains from top-performing micro-cap holdings. Micro-cap valuations remain near 25-year lows versus large caps, with small- and micro-cap earnings growth expected to outpace large caps in 2026–2027.

NAV/share declined 11.6% in 2025, but distribution coverage improved to 2.1x, and RMT outperformed its CEF category across multiple timeframes. RMT's portfolio remains diversified, with industrials and tech as top sectors and a 5.97% yield based on recent distributions. Microcap volatility and interest rate sensitivity remain key risks, but RMT has historically limited drawdowns relative to indices.

NEW YORK, June 24, 2026 /PRNewswire/ --  Average weekly trading volume of approximately 531,385 shares Fund's adviser has more than 50 years of small- and micro-cap investment experience CLOSING PRICES AS OF 05/31/26 NAV 15.73 MKT 14.04 AVERAGE ANNUAL TOTAL RETURN AS OF 05/31/26 NAV (%) MKT (%) One-Month* 6.21 6.20 Year to Date* 35.72 36.93 One-Year 70.80 73.35 Three-Year 28.50 29.82 Five-Year 11.90 11.99 10-Year 15.25 15.81 *Not Annualized Important Performance and Expense Information All performance information reflects past performance, is presented on a total return basis, net of the Fund's investment advisory fee, and reflects the reinvestment of distributions. Past performance is no guarantee of future results Current performance may be higher or lower than performance quoted.

Material Transfer Agreements provide access to leading lipid nanoparticle formulations to validate delivery of its proprietary payloads and accelerate development of in vivo Regenerative Macrophage Therapy  Development programme complements Company's autologous engineered Regenerative Macrophage Therapy, RTX001, in Ph 1/2 clinical development Together, programmes aim to broaden patient population able to benefit from Regenerative Macrophage Therapy EDINBURGH, United Kingdom and LONDON, June 17, 2026 (GLOBE NEWSWIRE) -- Resolution Therapeutics Limited (“Resolution” or “Company”), a clinical-stage biopharmaceutical company pioneering Regenerative Macrophage Therapy (RMT) in inflammatory and fibrotic diseases, today announced the execution of Material Transfer Agreements with independent, best-in-class lipid nanoparticle (LNP) technology providers. Under the agreements, Resolution will conduct systematic assessments of LNP formulations for the engineering of the myeloid compartment in vivo, with preliminary results expected later this year.

NEW YORK, June 1, 2026 /PRNewswire/ -- Royce Micro-Cap Trust, Inc. (NYSE-RMT) has declared a quarterly distribution of $0.21 per share on its Common Stock. The distribution, optionally payable in additional shares of Common Stock, or in cash by specific stockholder election, is to be paid on June 29, 2026, to stockholders of record at the close of business on June 11, 2026 (ex-dividend on June 11, 2026).

NEW YORK, May 20, 2026 /PRNewswire/ -- Average weekly trading volume of approximately 641,137 shares Fund's adviser has more than 50 years of small- and micro-cap investment experience CLOSING PRICES AS OF 04/30/26 NAV 14.81 MKT 13.22 AVERAGE ANNUAL TOTAL RETURN AS OF 04/30/26 NAV (%) MKT (%) One-Month* 15.88 16.89 Year to Date* 27.78 28.93 One-Year 72.98 74.60 Three-Year 26.07 26.78 Five-Year 10.83 11.28 10-Year 14.60 15.21 *Not Annualized Important Performance and Expense Information All performance information reflects past performance, is presented on a total return basis, net of the Fund's investment advisory fee, and reflects the reinvestment of distributions. Past performance is no guarantee of future results Current performance may be higher or lower than performance quoted.

RTX001 is an engineered Regenerative Macrophage Therapy for end-stage liver disease (ESLD) with anti-inflammatory and anti-fibrotic properties These new preclinical data demonstrate RTX001's pharmacology, safety, tolerability, and efficacy in mouse models, with reduced fibrosis and inflammation observed Results confirm RTX001's positive preclinical safety and therapeutic profile ahead of interim results from Resolution's Phase I/II EMERALD clinical trial, expected H2 2026 EDINBURGH, United Kingdom and LONDON, May 12, 2026 (GLOBE NEWSWIRE) -- Resolution Therapeutics Limited (“Resolution” or “Company”), a clinical-stage biopharmaceutical company pioneering Regenerative Macrophage Therapy (RMT) in inflammatory and fibrotic diseases, will present key preclinical data today on its Regenerative Macrophage Therapy RTX001 in an oral presentation at the ASGCT Annual Meeting, being held from 11-15 May, 2026, in Boston, Massachusetts, US. The presentation will outline Resolution's strategy for testing the safety, biodistribution and pharmacology of RTX001, the Company's engineered RMT.

NEW YORK, May 4, 2026 /PRNewswire/ -- Average weekly trading volume of approximately 772,582 shares Fund's adviser has more than 50 years of small- and micro-cap investment experience CLOSING PRICES AS OF 03/31/26 NAV 12.78 MKT 11.31 AVERAGE ANNUAL TOTAL RETURN AS OF 03/31/26 NAV (%) MKT (%) One-Month* -5.93 -5.78 Year to Date* 10.26 10.31 One-Year 47.36 44.95 Three-Year 18.33 17.97 Five-Year 8.62 8.95 10-Year 13.33 14.00 *Not Annualized Important Performance and Expense Information All performance information reflects past performance, is presented on a total return basis, net of the Fund's investment advisory fee, and reflects the reinvestment of distributions. Past performance is no guarantee of future results Current performance may be higher or lower than performance quoted.

NEW YORK, March 25, 2026 /PRNewswire/ -- Average weekly trading volume of approximately 742,172 shares Fund's adviser has more than 50 years of small- and micro-cap investment experience CLOSING PRICES AS OF 02/28/26 NAV 13.82 MKT 12.21   AVERAGE ANNUAL TOTAL RETURN AS OF 02/28/26 NAV (%) MKT (%) One-Month* 7.05 6.27 Year to Date* 17.22 17.07 One-Year 43.30 42.68 Three-Year 19.44 18.55 Five-Year 9.28 9.74 10-Year 14.90 15.56 *Not Annualized Important Performance and Expense Information All performance information reflects past performance, is presented on a total return basis, net of the Fund's investment advisory fee, and reflects the reinvestment of distributions. Past performance is no guarantee of future results.

Eight of the portfolio's 11 equity sectors made a positive impact on calendar year performance, led by Industrials, Materials, and Financials. nLIGHT differentiates itself via vertical integration, domain knowledge, and manufacturing capabilities to deliver cutting edge solutions, increasingly to government and defense organizations. Shares of Sprott outperformed as gold prices broke out to record highs amid elevated geopolitical risk, central bank buying, and a weaker U.S. dollar.